Last Posted: Nov 08, 2019
- Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
Elsayegh Nisreen et al. Cancer medicine 2018 7(6) 2718-2726 - Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia Valentina et al. Cancer 2019 Nov - Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program.
Dwarte Tanya et al. Hereditary cancer in clinical practice 2019 1730 - High Oncotype Recurrence Score, Hereditary Cancer Syndromes, and Referral for Genetic Testing.
Goel Arun Kumar et al. Clinical breast cancer 2019 Oct - Prevalence and spectrum of MLH1 , MSH2 , and MSH6 pathogenic germline variants in Pakistani colorectal cancer patients.
Rashid Muhammad Usman et al. Hereditary cancer in clinical practice 2019 1729 - Regarding the Yin and Yang of Precision Cancer- Screening and Treatment: Are We Creating a Neglected Majority?
McBride Colleen M et al. International journal of environmental research and public health 2019 Oct 16(21) - CMS Aims to Broaden Coverage for NGS Testing in Breast, Ovarian Cancer -Expansion would include patients with risk factors for inherited susceptibility mutations
I Ingram, MedPage Today, October 31, 2019 - Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer.
Karam Rachid et al. JAMA network open 2019 Oct 2(10) e1913900 - Breast cancer risk assessment in patients who test negative for a hereditary cancer syndrome.
Breit Caroline et al. American journal of surgery 2019 Oct - Testing for Honesty
L Schlager, Cure, October 2019
.png)
No hay comentarios:
Publicar un comentario